| ID Source | ID |
|---|---|
| PubMed CID | 7014 |
| CHEMBL ID | 412873 |
| SCHEMBL ID | 847129 |
| MeSH ID | M0045265 |
| Synonym |
|---|
| KBIO1_000631 |
| DIVK1C_000631 |
| sparteine, d-isomer |
| d-sparteine |
| brn 3540601 |
| (7r-(7alpha,7aalpha,14alpha,14abeta))-dodecahydro-7,14-methano-2h,6h-dipyrido (1,2-a:1',2'-e)(1,5)diazocine |
| 7,14-methano-2h,6h-dipyrido(1,2-a:1',2'-e)(1,5)diazocine, decahydro-, (7r,7ar,14r,14as)- |
| 6-alpha,7-beta,9-beta,11-beta-sparteine |
| (+)-sparteine |
| pachycarpine |
| nsc376144 |
| IDI1_000631 |
| (-)-sparteine sulfate salt |
| tocosamine (sulfate pentahydrate) |
| [7s-(7.alpha.,7a.alpha.,14.alpha.,14a.beta.)]-dodecahydro-7,14-methano-2h,6h-dipyrido[1,2-a:1',2'-e][1,5]diazocine |
| depasan (sulfate pentahydrate) |
| NINDS_000631 |
| NCGC00142614-02 |
| NCGC00142614-03 |
| CHEMBL412873 |
| HMS501P13 |
| S0461 |
| (10s,1r,2r,9r)-7,15-diazatetracyclo[7.7.1.0<2,7>.0<10,15>]heptadecane |
| 492-08-0 |
| 5-23-05-00497 (beilstein handbook reference) |
| SCHEMBL847129 |
| AKOS022176272 |
| (7r,7ar,14r,14as)-dodecahydro-7,14-methano-2h,6h-dipyrido[1,2-a:1',2'-e][1,5]diazocine |
| mfcd00869353 |
| DS-3062 |
| (1r,2r,9r,10s)-7,15-diazatetracyclo[7.7.1.0^{2,7}.0^{10,15}]heptadecane |
| HY-W008350 |
| CS-W008350 |
| (+)-sparteine, >=98.0% (gc) |
| bdbm50480276 |
| (7r,7ar,14r,14as)-dodecahydro-2h,6h-7,14-methanodipyrido[1,2-a:1',2'-e][1,5]diazocine |
| (+)-sparteine (pachycarpine) |
| SLRCCWJSBJZJBV-TUVASFSCSA-N |
| Q66604441 |
| sparteine-(+) |
| A871833 |
| (7r,7ar,14r,14as)-dodecahydro-2h,6h-7,14-methanodipyrido[1,2-a:1,2-e][1,5]diazocine |
| DTXSID401317646 |
| (1r,2s,9r,10r)-7,15-diazatetracyclo[7.7.1.02,7.010,15]heptadecane |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Cytochrome P450 2D6 | Homo sapiens (human) | IC50 (µMol) | 60.0000 | 0.0000 | 2.0151 | 10.0000 | AID262947 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| monooxygenase activity | Cytochrome P450 2D6 | Homo sapiens (human) |
| iron ion binding | Cytochrome P450 2D6 | Homo sapiens (human) |
| oxidoreductase activity | Cytochrome P450 2D6 | Homo sapiens (human) |
| oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | Cytochrome P450 2D6 | Homo sapiens (human) |
| heme binding | Cytochrome P450 2D6 | Homo sapiens (human) |
| anandamide 8,9 epoxidase activity | Cytochrome P450 2D6 | Homo sapiens (human) |
| anandamide 11,12 epoxidase activity | Cytochrome P450 2D6 | Homo sapiens (human) |
| anandamide 14,15 epoxidase activity | Cytochrome P450 2D6 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| mitochondrion | Cytochrome P450 2D6 | Homo sapiens (human) |
| endoplasmic reticulum | Cytochrome P450 2D6 | Homo sapiens (human) |
| endoplasmic reticulum membrane | Cytochrome P450 2D6 | Homo sapiens (human) |
| cytoplasm | Cytochrome P450 2D6 | Homo sapiens (human) |
| intracellular membrane-bounded organelle | Cytochrome P450 2D6 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID337605 | Displacement of [3H]quinuclidinyl benzilate from muscarinic ACh receptor | 1994 | Journal of natural products, Sep, Volume: 57, Issue:9 | Binding of quinolizidine alkaloids to nicotinic and muscarinic acetylcholine receptors. |
| AID262947 | Inhibition of human CYP2D6 expressed in Escherichia coli JM109 | 2006 | Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8 | Catalytic site prediction and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking. |
| AID397122 | Inhibition of HIV1 RT | |||
| AID1148099 | Binding affinity to magnesium salt in methanol-d4 solvent by proton magnetic resonance analysis | 1977 | Journal of medicinal chemistry, Dec, Volume: 20, Issue:12 | Analogues of sparteine. 5. Antiarrhythmic activity of selected N,N'-disubstituted bispidines. |
| AID337604 | Displacement of [3H]nicotin from nicotinic ACh receptor | 1994 | Journal of natural products, Sep, Volume: 57, Issue:9 | Binding of quinolizidine alkaloids to nicotinic and muscarinic acetylcholine receptors. |
| AID1148098 | Binding affinity to calcium salt in methanol-d4 solvent by proton magnetic resonance analysis | 1977 | Journal of medicinal chemistry, Dec, Volume: 20, Issue:12 | Analogues of sparteine. 5. Antiarrhythmic activity of selected N,N'-disubstituted bispidines. |
| AID184166 | Compound was evaluated for percent inhibition of antiarrhythmic activity catalyzed by cytochrome P-450 UT-H in liver microsomes of rats | 1984 | Journal of medicinal chemistry, Sep, Volume: 27, Issue:9 | Oxidation of sparteines by cytochrome P-450: evidence against the formation of N-oxides. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.46) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||